RE-BVS – Piemonte Repository

Sfoglia per AUTORE
WOLF J
Collezione AOU San Luigi di Orbassano

Items : 5

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. in Future oncology (London, England) / Future Oncol. 2025 Mar 24:1-12. doi: 10.1080/14796694.2025.2474789.

2025
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. in The New England journal of medicine / N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21.

2023
AOU San Luigi di Orbassano

Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. in Lancet (London, England) / Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7.

2023
AOU San Luigi di Orbassano

Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2022 Oct;172:94-99. doi: 10.1016/j.lungcan.2022.08.008. Epub 2022 Aug 12.

2022
AOU San Luigi di Orbassano

Felip E; Smit EF; Molina-Vila MA; Dafni U; Massuti B; Berghmans T; de Marinis F; Passiglia F; Dingemans AC; Cobo M; Viteri S; Britschgi C; Cuffe S; Provencio M; Merkelbach-Bruse S; Andriakopoulou C; Kammler R; Ruepp B; Roschitzki-Voser H; Peters S; Wolf J; Stahel R;

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5.

2021
AOU San Luigi di Orbassano

Novello S; F Loong HH; Lin BK; Lin AB; Sashegyi A; Soldatenkova V; Davis HM; Elamin Y; Wolf J; Park K; Drilon A; Zhou CC; Solomon BJ; Arriola E; Pérol M; Goto K; Santini FC;